MARKET WIREInvesting.com • 6h ago
Equillium stock price target maintained at $20 by Piper SandlerInvesting.com report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
Why EQ Stock dropped -3.52% Today — RQD Quant Desk Flash
$1.37 -3.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.36
Equillium Inc. (EQ) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $111.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EQ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EQ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Equillium Inc. (NASDAQ: EQ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.37 (-3.52% 1D, market cap $111.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EQ ranks #478 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EQ compare to ANIX and TLSA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EQ carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIX (Anixa Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $114.7M) and TLSA (Tiziana Life Sciences Ltd.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M). Among the 5-stock peer group, EQ leads on earnings multiple (N/A) while EQ leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EQ?
▼
Per EQ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746466), Equillium Inc. generated $0 in revenue (-100.0% YoY), -$22.4M in net income, and -$22.8M in free cash flow against $31.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.36 (-0.82%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EQ)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY EQ SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)
FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.41-15.6% Next Q
50
Q2 (-2Q)Grade D$1.19+3.4% Next Q
47
Q3 (-1Q)Grade D$1.23+11.4% Next Q
45
CurrentGrade D-$1.37-7% Hist 90D α
42
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EQ Turnaround Squeeze
While EQ currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.77) and Max Pain ($1.44) forces dealer call-delta covering toward $3.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EQ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EQ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EQ Stock dropped -3.52% Today — RQD Quant Desk Flash
Equillium Inc. (EQ) dropped -3.52% to $1.37, trading at 22% of its 52-week range ($0.76 – $3.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 22% of its 52-week range ($0.76 – $3.54) with RSI-14 at 43.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.37 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live EQ Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 9h ago
Equillium, Inc. (EQ) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
CATALYSTMoomoo • 12h ago
Leerink Partners Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $6Moomoo report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 15h ago
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504Yahoo Finance report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Nigeria • 18h ago
Equillium doses first patient in EQ504 phase 1 trial By Investing.comInvesting.com Nigeria report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 21h ago
EQ Q2 2026 Earnings: Narrower-Than-Expected Loss Per Share as Revenue Stays Pre-Commercial - EPS Growth Reporthttps://www.dars.gov.et/ report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 7d ago
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in additi
MARKET WIREBenzinga • 7d ago
Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory DiseasesEquillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in Australia in its Phase 1
MARKET WIREBenzinga • 7d ago
12 Health Care Stocks Moving In Monday's Pre-Market SessionGainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9
MARKET WIREBenzinga • 21d ago
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EQ)
- ✓Walkthrough of EQ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EQ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.84%▼ DESCENDING CHANNEL
2026-10-30O $1.38H $1.42L $1.29C $1.37VOL 310.6K
RES: $2.08SUP: $0.94SMA50: $1.77SMA200: $2.08
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EQ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EQ today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EQ. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EQ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EQ)
Health Care Rank #478 of 1016
⚔️ ANIX vs EQ Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EQ vs. ANIX, TLSA, NRXP, NERV)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Equillium Inc. (EQ) ranks #478 by composite RQD confidence (42/100, grade D-) and #646 by equity capitalization ($111.3M). Within this direct 5-issuer industry benchmark cohort, EQ leads on earnings valuation at N/A trailing P/E, while EQ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with EQ at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EQ
ACTIVE
Equillium Inc. | D- | 42/100 | — | — | -35.0% | -3.52% | $111.3M | Benchmark Subject |
| ANIX Anixa Biosciences Inc. | E | 32/100 | — | — | -35.0% | -5.45% | $114.7M | /anix-vs-eq → |
| TLSA Tiziana Life Sciences Ltd. | D+ | 55/100 | — | — | — | -11.57% | $115.1M | /tlsa-vs-eq → |
| NRXP NRX Pharmaceuticals Inc. | D- | 36/100 | — | 58.8% | -35.0% | -14.66% | $115.2M | /nrxp-vs-eq → |
| NERV Minerva Neurosciences Inc | D- | 38/100 | — | — | -35.0% | +3.57% | $107.0M | /nerv-vs-eq → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001746466In its most recent audited fiscal period (FY2025, filed 2025-12-31), Equillium Inc. (EQ) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $41.1M , and -100.0% cumulative change since FY2023) , GAAP net income of -$22.4M, operating cash flow of -$22.7M, and free cash flow of -$22.8M (-19.3% YoY). On the balance sheet, EQ closed FY2025 with $31.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$22.4M | -$22.7M | -$22.8M | $31.9M | — |
| FY2024 (FY) | 2024-12-31 | $41.1M | -$8.1M | -$19.0M | -$19.1M | $25.6M | — |
| FY2023 (FY) | 2023-12-31 | $36.1M | -$13.3M | -$21.8M | -$21.8M | — | — |
3. EQ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EQ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Equillium Inc. (NASDAQ: EQ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.37 (-3.52% 1D, market cap $111.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EQ ranks #478 in composite RQD confidence.
How does EQ compare to ANIX and TLSA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EQ carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIX (Anixa Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $114.7M) and TLSA (Tiziana Life Sciences Ltd.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M). Among the 5-stock peer group, EQ leads on earnings multiple (N/A) while EQ leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EQ?
Per EQ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746466), Equillium Inc. generated $0 in revenue (-100.0% YoY), -$22.4M in net income, and -$22.8M in free cash flow against $31.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EQ trading relative to its 50-day, 200-day, and 52-week technical levels?
EQ last traded at $1.37 (-3.52% on volume of 310,727 shares), positioning the stock -22.60% below its 50-day simple moving average ($1.77) and -34.13% below its 200-day simple moving average ($2.08). Across its 52-week range of $0.76 to $3.54, EQ sits at the 21.9% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).
EQ Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is EQ stock moving today?
Why EQ Stock dropped -3.52% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
EQ — Equillium Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:40Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, EQ scores 42 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 8 out of 20, reflecting ROIC of -35% and an FCF yield of -20.48%; for a prospective investor, this means the business is currently consuming cash rather than generating it, so any valuation rests on future execution rather than present earnings power. The whale/13F flow pillar scores 9 out of 20 on institutional accumulation and options positioning, a modest signal that does not offset the weaker fundamentals. The insider conviction pillar scores 3 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar, which signals limited insider-driven confidence in the source data. The macro regime fit pillar scores 12 out of 20 with a beta of 1.0 and sector sensitivity noted, indicating market-level volatility is roughly in line with the broad market. The forensic balance sheet pillar scores 10 out of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 1 out of 9, and a Debt/Equity ratio of 0.5; the weak Piotroski reading is the most important red flag for an investor weighing the stock today. Upside drivers would require evidence of cash-flow inflection and improved forensic scores; the valuation tradeoff is that a market capitalization of $111.3M against negative cash generation leaves little margin of safety in the current framework.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-23.6M | $-22.4M | N/A | $-22.8M | $30.3M | N/A |
| FY 2024 | $41.1M | $-8.3M | $-8.1M | N/A | $-19.1M | $18.1M | N/A |
| FY 2023 | $36.1M | $-14.5M | $-13.3M | N/A | $-21.8M | N/A | N/A |
Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1 out of 9, and the Debt/Equity ratio is 0.5. Reported operating losses persist across all three periods, and FY 2025 cash of $30.3M is the highest cash figure in the table, though the source does not provide a debt figure to assess net liquidity.
Open Questions
- What are the company's products, commercial partners, and revenue model, given that FY 2025 revenue is reported as $0.0M?
- What is the debt balance, since the debt field is N/A across all periods, and how does it affect net liquidity?
- What drove the decline in revenue from $41.1M in FY 2024 to $0.0M in FY 2025?
- What are the EPS figures, since EPS is N/A across all reported periods?
- What institutional, insider, and options positioning exists, given that holder data is absent?
EQ Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Equillium Inc. (EQ) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 6h ago
Equillium stock price target maintained at $20 by Piper Sandler Investing.com report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 9h ago
Equillium, Inc. (EQ) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Moomoo • 12h ago
Leerink Partners Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $6 Moomoo report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 15h ago
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 Yahoo Finance report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Nigeria • 18h ago
Equillium doses first patient in EQ504 phase 1 trial By Investing.com Investing.com Nigeria report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 21h ago
EQ Q2 2026 Earnings: Narrower-Than-Expected Loss Per Share as Revenue Stays Pre-Commercial - EPS Growth Report https://www.dars.gov.et/ report covering Equillium Inc. (EQ) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 7d ago
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in additi
🟡 MARKET WIRE Benzinga • 7d ago
Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in Australia in its Phase 1
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EQ Bull vs. Bear Conversation Board — What's Your Call at $1.37?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EQ 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.21 (-11.7%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is EQ (D- • RQD 42/100) a Buy at $1.37?
Welcome to the EQ (Equillium Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.05 (-23.4%)
Spot @ $1.37 Pump the brakes on EQ — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on EQ, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Equillium Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.73 (+26.3%)
Spot @ $1.37 EQ cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on EQ, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.37 (52-wk range $0.76 - $3.54), any beat on forward guidance forces shorts and underweight funds to chase.